Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years?
On March 8, Ben Snider, Goldman Sachs senior equity strategist, joined CNBC to discuss the state of the economy today. Snider noted that the key struggle has been the market struggle to assess the forward trajectory of the economy. The market entered this year with optimism for the growth trajectory. However, over the past few weeks, we have seen a very sharp downturn. There is good news to extract from the scenario. Snider explained that if we look at where the market is priced today, it seems much more reasonable. Therefore the base case remains the same the economy is in good shape and is growing. He also noted that a confirmation of the growth came in with the jobs report, moreover, earnings are still growing, meaning that the equity market should be moving higher too.
However, the key question that remains unanswered is what sectors investors should look forward to. Most of the sectors have been volatile. Therefore, as per Snider, the best approach would be not to go all in for a single sector. He likes healthcare, which has been one of the best-performing sectors in the market so far. This is because despite the performance the sector is still trading at the lowest valuations compared to the market. Snider mentioned that this may be a good buying period as historical data tells us that when an investor buys the S&P 500 down 5%, it generates a positive return on investment over the next 5 months 85% of the time.
Moreover, Goldman Sachs has anticipated moderate yet resilient global growth in 2025, driven by the strong performance of the United States. The firm expects the US economy to be a primary driver of global growth, supported by a robust labor market, consistent consumer spending, solid credit conditions, sufficient liquidity, and increased capital spending related to AI. In addition, regarding the tariff situation, Goldman Sachs believes that the 'Fed Put' will come into play and ease monetary policy, however, terminal rates are expected to be higher than previously anticipated.
To curate the list of the 10 best growth stocks to invest in for the next 10 years, we looked at various online rankings. Using these rankings we aggregated a list of best growth stocks for the next 10 years. Next, we checked the sales growth of each stock from Seeking Alpha and added only those companies that have grown more than 15% over the past 5 years. Lastly, we ranked the stocks in ascending order of the number of hedge fund holders, sourced from Insider Monkey's Q4 2024 database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
A patient undergoing MRI scanning to effectively diagnose Liver Diseases.
Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that focuses on creating precision genetic medicines using base editing technologies for genetic disorders. Its base editing technology is designed to make precise and efficient single-base changes at targeted genomic sequences, without making double-stranded breaks in the DNA. Its pipeline products include BEAM-101, BEAM-201, BEAM-301, and BEAM-302, which are used for serious diseases.
On March 10, Beam Therapeutics Inc. (NASDAQ:BEAM) was upgraded to Buy from Hold Jones Research analyst Soumit Roy. The analyst has set a price target of $34. Roy noted that the company announced encouraging preliminary data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD). BEAM-302 is a medication that uses a liver-targeting lipid nanoparticle to deliver a guide RNA and an mRNA that encodes a base editor, which is designed to correct the PiZ mutation that causes AATD. The firm has increased the probability of success against AATD to 35% from 15% and also increased its adjusted peak sales to $1.9 billion in 2036, noting that BEAM-302 could be a one-time treatment for AATD. Jones Research believes that the data de-risks the company's platform on multiple levels. Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best growth stocks to invest in for the next 10 years.
Overall, BEAM ranks 9th on our list of best growth stocks to invest in for the next 10 years. While we acknowledge the potential of BEAM as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BEAM but that trades at less than 5 times its earnings, check out our report about the .
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Geopolitics dominates, before Fed takes the stage
A look at the day ahead in European and global markets from Wayne Cole. You know it's crazy times, when speculation Putin sent his body double to Alaska doesn't sound so outlandish. What does seem clear is that President Trump has shifted back to echoing Moscow's line, tweeting Kremlin talking points about Crimea and Zelenskiy. Putin's position seems to be that Ukraine should give up all the land Russia has taken, and much that it has failed to take in more than three years of fighting. This has been repeatedly ruled out by Zelenskiy and European leaders, and it's notable they will be by his side in Washington when he meets Trump later today. Markets have judged there is a diminished threat of further U.S. sanctions or tariffs on Russian oil exports, and oil prices are down modestly with Brent off 0.3%. Share markets are mostly firmer as Japan and Taiwan make more records, and Chinese blue chips scale a 10-month top. European stock futures are up 0.2% or so, as are Wall St futures. Valuations have been underpinned by a solid earnings season as Goldman notes S&P 500 EPS grew 11% on the year and 58% of companies raised their full-year guidance. This week's results will provide some colour on the health of consumer spending with Home Depot, Target, Lowe's and Walmart all reporting. For monetary policy the main event will be the Federal Reserve's Jackson Hole jamboree where Chair Powell speaks on the economic outlook and the Fed's policy framework on Friday, though there doesn't seem to be a Q&A as yet. ECB President Christine Lagarde and Bank of England Governor Andrew Bailey are on panel discussions. Futures are about 85% priced for a Fed rate cut in September so anything less than dovish from Powell would be a setback for debt markets. While Fed expectations are anchoring short-term yields, the long end continues to fret about inflation, budget deficit and the politicisation of monetary policy, so steepening the yield curve. European bond yields have also been on the rise, perhaps in part on a realisation of how much governments are going to have to borrow to cover increased defence spending. Key developments that could influence markets on Monday: - EU trade figures for June, US NAHB housing survey (By Wayne Cole; Editing by Jacqueline Wong) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Citi Raised the Firm's PT on JD.com (JD), Kept a Buy Rating
Inc. (NASDAQ:JD) is one of the Undervalued Cyclical Stocks to Buy According to Hedge Funds. On August 14, Citi analyst Alicia Yap raised the firm's price target on Inc. (NASDAQ:JD) from $42 to $44, while maintaining a Buy rating on the stock. The improved sentiment for the company follows its announcement of robust fiscal second-quarter 2025 results. Inc. (NASDAQ:JD) delivered RMB356.7 billion in revenue for the quarter, up 22.4% year-over-year, exceeding Wall Street estimates. Management noted that its Retail segment showed solid performance with revenue growing 20.6% and operating margins improving 4.5%. This was its highest margin in any promotional quarter. A wide and imposing view of a supply chain distribution center, illustrating the company's technology capabilities. Inc. (NASDAQ:JD) is an e-commerce company operating through its retail mobile apps and website, offering online retail and marketplace services. While we acknowledge the potential of JD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23 minutes ago
- Yahoo
What To Expect From Premier's (PINC) Q2 Earnings
Healthcare tech company Premier (NASDAQ:PINC) will be reporting earnings this Tuesday morning. Here's what you need to know. Premier beat analysts' revenue expectations by 7.4% last quarter, reporting revenues of $261.4 million, down 8.9% year on year. It was a very strong quarter for the company, with a beat of analysts' EPS estimates and an impressive beat of analysts' full-year EPS guidance estimates. Is Premier a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Premier's revenue to decline 28.5% year on year to $250.4 million, a reversal from the 2.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.34 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Premier has missed Wall Street's revenue estimates four times over the last two years. Looking at Premier's peers in the healthcare technology for providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Privia Health delivered year-on-year revenue growth of 23.4%, beating analysts' expectations by 10.9%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Privia Health traded up 4% following the results while Omnicell's stock price was unchanged. Read our full analysis of Privia Health's results here and Omnicell's results here. There has been positive sentiment among investors in the healthcare technology for providers segment, with share prices up 7.2% on average over the last month. Premier is up 19.2% during the same time and is heading into earnings with an average analyst price target of $22.33 (compared to the current share price of $24.95). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
